Scholarlink

Objective <p>Drug resistance remains a major clinical challenge in advanced lung adenocarcinoma. Identifying commonly dysregulated resistance-associated genes may provide mechanistic insights for novel therapeutic strategies.</p> Methods <p>RNA-seq data from eight TCGA LUAD patients with documented TKI treatment were analyzed using the limma empirical Bayes framework for exploratory differential expression analysis. WDR17 association with clinicopathological features was evaluated in the TCGA cohort. Single-cell transcriptomics from publicly available datasets (GSE139386 and GSE260499) was used to characterize WDR17 distribution in TKI-resistant cell lines. In vitro experiments assessed the functional relevance of WDR17 in drug sensitivity.</p> Results <p>Exploratory differential expression analysis identified WDR17 as significantly downregulated in the non-responding group (log2 FC =  − 1.11, adjusted P = 0.026). In the broader TCGA-LUAD cohort, high WDR17 expression was associated with longer overall survival (HR = 0.78, 95% CI: 0.67–0.91, P &lt; 0.001). Single-cell analysis revealed that WDR17 was predominantly expressed in a cell state characterized by protein homeostasis and metabolic stress. Computational estimation using the EPIC algorithm suggested a positive correlation between WDR17 expression and CD8 + T-cell infiltration (P &lt; 0.05). In vitro experiments confirmed that WDR17 overexpression enhanced crizotinib sensitivity in resistant cells, whereas knockdown reduced sensitivity in parental cells.</p> Conclusion <p>This exploratory study identified WDR17 as a candidate biomarker associated with TKI resistance in lung adenocarcinoma, potentially involved in maintaining protein homeostasis and metabolic balance. These preliminary findings warrant validation in larger, independent cohorts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploratory multiomics analysis identifies WDR17 as a potential biomarker of tyrosine kinase inhibitor resistance in lung adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月28日

查看全文
  • Yuan Xu,
  • Liping Li,
  • Zhouhua Li,
  • Yanqiang Yang,
  • Hongquan Xing,
  • Xuehua Ma,
  • Xinyi Zhang

摘要

Objective

Drug resistance remains a major clinical challenge in advanced lung adenocarcinoma. Identifying commonly dysregulated resistance-associated genes may provide mechanistic insights for novel therapeutic strategies.

Methods

RNA-seq data from eight TCGA LUAD patients with documented TKI treatment were analyzed using the limma empirical Bayes framework for exploratory differential expression analysis. WDR17 association with clinicopathological features was evaluated in the TCGA cohort. Single-cell transcriptomics from publicly available datasets (GSE139386 and GSE260499) was used to characterize WDR17 distribution in TKI-resistant cell lines. In vitro experiments assessed the functional relevance of WDR17 in drug sensitivity.

Results

Exploratory differential expression analysis identified WDR17 as significantly downregulated in the non-responding group (log2 FC =  − 1.11, adjusted P = 0.026). In the broader TCGA-LUAD cohort, high WDR17 expression was associated with longer overall survival (HR = 0.78, 95% CI: 0.67–0.91, P < 0.001). Single-cell analysis revealed that WDR17 was predominantly expressed in a cell state characterized by protein homeostasis and metabolic stress. Computational estimation using the EPIC algorithm suggested a positive correlation between WDR17 expression and CD8 + T-cell infiltration (P < 0.05). In vitro experiments confirmed that WDR17 overexpression enhanced crizotinib sensitivity in resistant cells, whereas knockdown reduced sensitivity in parental cells.

Conclusion

This exploratory study identified WDR17 as a candidate biomarker associated with TKI resistance in lung adenocarcinoma, potentially involved in maintaining protein homeostasis and metabolic balance. These preliminary findings warrant validation in larger, independent cohorts.